Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide vs rasagiline for fatigue in Parkinson's disease
2023-503713-29-00Phase 4Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Sep 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Parkinson's disease (PD) and asthenia comparing Safinamide arm with Rasagiline arm (2 arms). Primary endpoint: Change in Fatigue Severity Scale (FSS) score. Planned start Sep 2023; status: authorised.
02
Drugs
safinamiderasagiline
03
Conditions
Parkinson's disease (PD)asthenia
Beyond the preview
Go deeper on 2023-503713-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503713-29-00.